Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
May 19, 2022

SwanBio raises $56m to advance new gene therapies for neurological conditions

SwanBio Therapeutics, a gene therapy company, has raised $56m through Series B financing round to advance gene therapies for neurological conditions.

Image: With the proceeds from the latest funding round, the company plans to advance therapies for neurological conditions. Credit: Dmitriy Gutarev from Pixabay.